GSK Gets FDA Approval for New Lung-Cancer Drug

By Adria Calatayud

 

GSK received U.S. Food and Drug Administration authorization to launch a new medicine for lung cancer, a move that bolsters its efforts to build a franchise in a disease that is the leading cause of cancer death.

The U.K. pharmaceutical company said late Tuesday that the FDA granted accelerated approval to its drug, marketed under the Nelkarmi brand and also known as neladalkib, for patients with a type of locally advanced or metastatic nonsmall-cell lung cancer who had previously received treatment.

This marks GSK's second approval in lung cancer this year after U.S. regulators gave the green light to the two most advanced products the drugmaker acquired as part of its $10.6 billion takeover of biotech company Nuvalent.

The company received FDA approval for its first medicine in lung cancer, Jideytro, in July. Executives at GSK previously indicated they expected Nelkarmi to represent the bigger sales opportunity of the two.

GSK Chief Executive Luke Miels said during a recent earnings call that the company is building critical mass in lung cancer. Under Miels, the company has moved to strengthen its oncology business, expanding its focus beyond the hematology and gynecologic cancers it had been targeting until recently into new types such as lung and gastrointestinal. It also turned to dealmaking to add new assets and sought to accelerate their clinical-development program.

In addition to Nelkarmi and Jideytro, GSK is testing a drug called ris-rez in late-stage clinical trials for a different type of lung cancer.

Nelkarmi, a once-daily pill, is designed to help address treatment resistance and disease that has spread to the brain, the company said. GSK is also evaluating it in a late-stage trial for an earlier stage of nonsmall-cell lung cancer, as well as for other solid tumors.

The FDA approval was based on an early and midstage study of the drug that showed clinically meaningful and durable responses in patients previously treated, GSK said.

While the early approval for Nelkarmi is positive, the larger opportunity will be in the first-line setting, for which GSK is running a head-to-head trial versus Roche's Alecensa, analysts at RBC Capital Markets wrote in a note to clients.

 

Write to Adria Calatayud at adria.calatayud@wsj.com

 

(END) Dow Jones Newswires

November 18, 2026 02:23 ET (07:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center